Wednesday, January 16, 2013

Marketing Mgr Food Sector Los Angeles


Seeking a Marketing Manager in Los Angeles. Full details follow!
TITLE: Marketing Manager
REPORTS TO: Director of Retail & Food Service (Director R&FS)
INDUSTRY: Seafood, Retail & Food Service
LOCATION: Downtown Los Angeles
TO APPLY: email resume and cover letter to Recruiter, Deborah Kaufman, at deborah@healthcare-recruiting.com


DESCRIPTION:

One of the world's leading seafood companies and largest producer of farmed salmon is seeking a hands-on Marketing Manager.  The emphasis of this position is developing brand(s) and creating additional margin through these brand(s).  This position requires a hands-on approach with the marketing manager being very active in all facets.   A marketing portfolio will need to be created for both Retail & Food Service (R&FS) that leverages market research. To this end, the Marketing Manager develops the tools for the Key Account Managers (KAMs) to grow the business; with the objective to stay ahead of competitors on Point-Of-Sale (POS), new products, branding and species.

The Marketing Manager must stay abreast of the competitive environment, market trends, and world events that could impact commercial plans. Flexibility is essential for this position; the Marketing Manager must be able to adjust plans and strategies according to a variety of changing conditions, including logistical demands and management direction.


RESPONSIBILITIES:

·       Marketing. Develops and implements marketing strategy, plan(s) and activities to maximize sales of an assigned brand/product. Including all elements of marketing such as but not limited to advertising, websites, social media, etc. Actively participate in every aspect of the plan using previous work experience.

·       Budget. Develops annual budget for execution of marketing strategy.

·       Project Coordination. Coordinates projects to implement new brands and products; must be able to take a project and run with it at any stage; strong project management skills required.

·       Market Research. Successfully interpret purchased and self-collected market intelligence to:

o   Develop brand concept & positioning.

o   Develop marketing plans for specific products, services, or business lines.

o   Reviews changes to the marketplace and industry and adjusts marketing plan accordingly.  Measuring success of strategies and proposes timely modifications to address shortcomings.

o   Make suggestions on marketing material.

o   Branding. Using the market research and other means analyzes brand performance, brand competitiveness, and product trends in the marketplace. Develops strategies for assigned brand based on research and analysis. Potential create a brand for our VAP.

·       New Product Development. Work with Director of R&FS on research and development of innovative products.

·       Packaging. Coordinate with graphic designer, to participate in creating packaging for new items and updating existing packaging.

·       Sales Support. Work with sales team to identify and implement appropriate sales strategies with proper POS support.

·       Vendor Administration.  Is point of contact with agencies, freelance designers & printers on creative development and negotiating cost.  Work with the marketing research firm collecting information.


QUALIFICATIONS:

·       Requires a bachelor's degree in Marketing with 5-7 years of experience. Additional training a plus.

·       Most recent work experience in marketing with a company of USD 50 million in annual sales.

·       CPG, food service and retail background experience required, and must be clearly visible on resume.

·       A background in food required, perishable a plus.

·       Planning. Experience in creating marketing plans & budgets required.

·       Branding. Experience in implementing, establishing and positioning new brands. Experience in planning and executing a comprehensive product launch. Track record of successful brand management and new brand development. Experience with brand positioning and repositioning.

·       Familiar with a variety of the field's concepts, practices, and procedures.

·       Relies on experience and judgment to plan and accomplish goals. Performs a variety of tasks.

·       A wide degree of creativity and latitude is expected.  Must be a self-starter and able to work independently.

·       Problem solving skills required.

·       Proven communication skills, both written and verbal, to clearly and concisely communicate within all levels of the organization as well as with external partners and agencies/vendors.

·       Highly organized, strong project manager with ability to multi-task and prioritize for optimal project execution. High degree of ownership and initiative.

·       Willing & able to travel nationally and internationally approximately 25% of the time.



Tuesday, January 15, 2013

Clinical Study News: Tenex Health TX1 System


Tenex Health Announces Publication of Prospective Clinical Study Results.
Full press release follows.
SOURCE: Tenex Health

LAKE FOREST, Calif.--(BUSINESS WIRE)—Jan. 15, 2013—
Tenex Health Inc. (www.tenexhealth.com), a pioneer in less-invasive treatment for musculoskeletal injuries, announced the recent publication of a prospective clinical study result in the American Journal of Sports Medicine (AJSM). The study entitled Fasciotomy and Surgical Tenotomy for Recalcitrant Lateral Elbow Tendinopathy describes the TX1 System as a safe and effective tool used in percutaneous tenotomy procedures in patients suffering from chronic tennis elbow.

The TX1 System was launched in the U.S. in February of 2012 and has been used in the treatment of about 3000 patients suffering from a wide range of tendon injuries – shoulder, elbow, knee, Achilles and plantar fascia. The TX1 System consists of a pen-like hand piece and console which allows for the physician to insert an 18g needle-like probe via a percutaneous approach that specifically cuts the damaged tendon tissue while preserving the healthy tissue. The intervention is conducted under local anesthesia and ultrasound guidance which provides for a safe and patient-friendly experience. The minimally invasive nature of the treatment and documented quick recovery times allows physicians to treat these patients earlier in their course.

“The safety, efficacy, tolerance and return to activity features of this treatment were as we had hoped, but quite frankly, exceeded our expectations. We feel the concept is truly a game changer. The features of this treatment modality to both physicians and patients are a real breakthrough,” reported Dr. Bernard Morrey, the Chief Medical Officer of Tenex Health.

The publication details the results of an independently conducted IRB-approved prospective study authored by faculty from Singapore General Hospital and the Mayo Clinic. The study revealed:
i.

Single treatment of 20 patients in an out-patient setting with no patient requirements of follow-up medications or physical therapy
ii.

No device or patient related complications occurred over 12 month follow-up period
iii.

Statistically significant improvement in pain within 1 week and sustained improvement for 12 months
iv.

Statistically significant improvement in quality of life measurement within 1 month and sustained improvement for 12 months
v.

Diagnostic ultrasound evidence consistent with a repaired tendon by 6 months of treatment
vi.

Efficacy of therapy sustained in 95% of patients at 12 month follow-up period

Jagi Gill, Founder and CEO of Tenex Health, added, “The rigor and follow-up of this clinical study clearly demonstrates a compelling option for the millions of patients suffering from tennis elbow. Furthermore, we are especially excited as the clinical results from this prospective study match what we have seen in the community at large in over 100 centers throughout the U.S.”
About Tenex Health Inc. Tenex Health, Inc. (www.tenexhealth.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. These tendon injuries affect more than 10 million Americans every year. The company’s proprietary TX1 Tissue Removal System is used to safely and specifically cut and debride diseased soft tissue in an outpatient setting using local anesthetic (www.fast-technique.com). Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures. The entire procedure is completed under local anesthesia and usually within 20 minutes.
Contact:
Tenex Health Inc.
Julie Flanery, 949-454-7500



Sunday, January 13, 2013

Clinical Trial News, Tivantinib Phase 2 Trial, Colorectal Cancer


Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer; Tivanitinib didn't meet primary Phase 2 trial endpoint.

Full press release below.

SOURCE:

TOKYO & WOBURN, Mass.--January 11, 2013 04:30 AM Pacific Time.--Daiichi Sankyo and ArQule announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer. Although the trial did not meet its primary endpoint of Progression-Free Survival, the analysis of the patients enrolled showed that median PFS was 8.3 months in the experimental arm, compared with 7.3 months in the control arm. Objective Response Rate a secondary endpoint, was 45 percent in the experimental arm versus 33 percent in the control arm but was not statistically significant. The PFS results obtained in both the control arm and the experimental arm were longer than expected compared to previously published historical norms. Additional data and analyses from this trial are planned for presentation at a future medical meeting and will include mature OS data as well as analyses of patient sub-groups, biomarker status and regional variability, including pre- and post study treatments. “We are encouraged by these findings that expand the body of data for tivantinib in CRC and offer the potential for further exploration,” said Reinhard von Roemeling, M.S., Vice President, Clinical Development-Oncology, Daiichi Sankyo. “We plan to continue discussions with key opinion leaders in the field of CRC to determine how best to proceed with further clinical development of tivantinib in this tumor type.”


Adverse events were reported at similar rates in the experimental and control arms, except for increased neutropenia observed in the experimental arm, with no discontinuations of treatment for this reason. No treatment-emergent adverse events leading to death were assessed as related to study treatment. Tivantinib was generally well tolerated in combination with the doses of cetuximab and irinotecan studied in this trial.
About the Phase 2 Trial
The 122 patients enrolled in this trial (US n=67; Russia n=39; Western Europe n=16) had unresectable CRC, progressed following first-line treatment and had tumors expressing the wild-type form of the KRAS gene. The primary objective of the trial was to assess the contribution of tivantinib to the irinotecan and cetuximab treatment regimen. The primary endpoint of the study was PFS, and secondary objectives included OS and ORR. Patients were randomized to receive tivantinib, 360 milligrams twice daily, plus irinotecan and cetuximab, or placebo plus irinotecan and cetuximab. The trial was conducted by Daiichi Sankyo, the co-developer with ArQule of tivantinib in all regions outside of certain territories in Asia.
Investor Conference Call
ArQule will host an investor conference call today at 9:00 a.m.
Date:
Friday, January 11, 2013
Time:
9:00 a.m. Eastern Time


Conference Call Dial-In Numbers

Domestic:
(877) 868-1831
International:
(914) 495-8595
Webcast:
A replay of the conference call will be available beginning approximately two hours after its completion for seven days and can be accessed by dialing toll-free 1-855-859-2056 and 1-404-537-3406 from outside the U.S. For archived calls, the access code is 88326775.
About Colorectal Cancer (CRC)
Colorectal cancer is the second leading cause of cancer-related deaths in the U.S. and is the third most common cancer in men and women. According to the National Cancer Institute, it is estimated that more than 140,000 new cases of colorectal cancer will be diagnosed in 2012, and an estimated 51,700 deaths from the disease will occur this year. The estimated incidence rate was 46 per 100,000 people during the period 2005-2009.
About MET and Tivantinib (ARQ 197)
Tivantinib is an orally administered, selective inhibitor of MET, a receptor tyrosine kinase, which is currently in Phase 2 clinical trials. In certain healthy adult cells, MET is present in low to normal levels to support natural cellular function, but in some cancer cells, MET is inappropriately and continuously activated. When abnormally activated, MET plays multiple roles in aspects of human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis.
Pre-clinical data have demonstrated that tivantinib inhibits MET activation in a range of human tumor cell lines and shows anti-tumor activity against several human tumor xenografts. In clinical trials to date, treatment with tivantinib has been generally well tolerated and has shown clinical activity in the tumors studied. Tivantinib has not yet been approved for any indication in any country.
About ArQule, Inc. and Daiichi Sankyo, Co., Ltd.
On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin Co., Ltd. has exclusive rights for development and commercialization.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the MET receptor tyrosine kinase. The Company’s pipeline consists of ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
This press release contains forward-looking statements regarding the clinical trials with tivantinib in combination with irinotecan and cetuximab in colorectal cancer conducted by the Company and Daiichi Sankyo Co., Ltd. as well as the Company’s agreement with Daiichi Sankyo. These statements are based on the Company’s current beliefs and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially. Positive information about pre-clinical and early stage clinical trial results does not ensure that later stage or larger scale clinical trials will be successful. For example, tivantinib alone or in a combination therapy may not demonstrate promising therapeutic effects in such trials; in addition, such therapies may not demonstrate an appropriate safety profiles in later stage or larger scale clinical trials, including among patients with underlying cirrhosis and compromised liver function, as a result of known or as yet unanticipated side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards or to justify further development. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing tivantinib or in obtaining irinotecan and cetuximab that could lead the Company or its partners to discontinue development. Even if later stage clinical trials are successful, unexpected concerns may arise from analysis of data or from additional data. Obstacles may arise or issues may be identified in connection with review of clinical data with regulatory authorities, and regulatory authorities may disagree with the Company’s view of the data or require additional data or information or additional studies. In addition, the planned timing of initiation and completion of clinical trials for tivantinib alone or in a combination therapy is subject to the ability of the Company or Daiichi Sankyo, its partner, to enroll patients, enter into agreements with clinical trial sites and investigators, and overcome other technical hurdles and issues related to the conduct of the trials for which each of them is responsible that may not be resolved. Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Positive pre-clinical data may not be supported in later stages of development. Furthermore, ArQule may not have the financial or human resources to successfully pursue drug discovery in the future. Moreover, Daiichi Sankyo has certain rights to unilaterally terminate the tivantinib license, co-development and co-commercialization agreement. If it were to do so, the Company might not be able to complete development and commercialization of tivantinib on its own. For more detailed information on the risks and uncertainties associated with the Company’s drug development and other activities, see the Company’s periodic reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements.
Contacts
Daiichi Sankyo, Inc. (US)
Tara Camp, 973-944-2393;
or
ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/Corp. Communications